[(2-bromophenyl)methyl](ethyl)dimethylazanium

• ChemBase编号: 1029
• 分子式: C11H17BrN+
• 平均质量: 243.16338
• 单一同位素质量: 242.05443655
• SMILES: Brc1c(C[N+](CC)(C)C)cccc1
• Canonical SMILES: CC[N+](Cc1ccccc1Br)(C)C
• InChI: InChI=1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1
• InChIKey: AAQOQKQBGPPFNS-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: [(2-bromophenyl)methyl](ethyl)dimethylazanium
• IUPAC传统名: bretylium
• 商标名: Bretylan; Bretylol; Darenthin; Darentin; Ornid
• 别名: Bretylium p-toluenesulfonate; Bretylium tolsylate; Bretylium tosylate; Bretylate; Bretylum; Bretylium

登记号

• CAS号: 59-41-6
• PubChem SID: 160964492; 46505320
• PubChem CID: 2431

理论计算性质

JChem

• 极化表面积: 0.0 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: true
• Acid pKa: 17.582369
• 质子受体: 0
• 质子供体: 0
• LogD (pH = 5.5): -1.1221335
• LogD (pH = 7.4): -1.1221335
• Log P: -1.1221335
• 摩尔折射率: 72.8857 cm^3
• 极化性: 23.680477 Å^3

ALOGPS 2.1

• 溶解度: 1.54e-04 g/l
• Log P: -1.36
• LOG S: -6.26

分子性质

理化性质

• 溶解度: Freely soluble

详细说明

DrugBank - DB01158

• Drug Groups: approved
• Description: Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation. The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels. Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.
• Indication: For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine.
• Pharmacology: Bretylium is a bromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. Bretylium also suppresses ventricular fibrillation and ventricular arrhythmias.
• Toxicity: Oral, mouse: LD₅₀ = 400 mg/kg. In the presence of life-threatening arrhythmias, underdosing with bretylium probably presents a greater risk to the patient than potential overdosage. However, one case of accidental overdose has been reported in which a rapidly injected intravenous bolus of 30 mg/kg was given instead of an intended 10 mg/kg dose during an episode of ventricular tachycardia. Marked hypertension resulted, followed by protracted refractory hypotension. The patient expired 18 hours later in asystole, complicated by renal failure and aspiration pneumonitis. Bretylium serum levels were 8000 ng/mL.
• Affected Organisms: Humans and other mammals
• Biotransformation: No metabolites have been identified following administration in man and laboratory animals.
• Half Life: The terminal half-life in four normal volunteers averaged 7.8±0.6 hours (range 6.9-8.1). During hemodialysis, this patient's arterial and venous bretylium concentrations declined rapidly, resulting in a half-life of 13 hours.
• External Links: Wikipedia; RxList